Skip to content
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Hematology · Hypereosinophilia

The Diagnostic Journey: Tests, Biopsies, and Imaging

At a Glance

Persistent hypereosinophilia is evaluated step by step with repeat blood tests, a blood smear, review of medicines and other causes, and sometimes genetic testing or bone marrow biopsy; heart tests matter because damage may begin before symptoms.

The diagnostic workup for persistent hypereosinophilia (HE) is a multi-step process designed to distinguish between reactive causes (like allergies or inflammatory diseases) and clonal causes (bone marrow disorders) [1][2].

Because eosinophils can damage organs before you feel any symptoms, your doctors will often run tests on your blood, your bone marrow, and your heart [3]. However, the workup is typically stepwise and individualized, beginning with a repeat CBC, medication and exposure review, and secondary-cause testing before proceeding to advanced imaging or biopsies.

The Peripheral Blood Smear

A peripheral blood smear is often the first deep look at your blood. A pathologist looks at a drop of your blood under a microscope to:

  • Identify Blasts: These are immature white blood cells. Their presence can be a sign of a more serious bone marrow disorder [4][5].
  • Check Eosinophil Appearance: While “normal-looking” eosinophils can still cause damage, abnormal shapes or sizes can provide clues to the underlying cause [6].
  • Examine Platelets: The smear helps confirm if your platelet count is truly low or high, or if the cells are clumping together [2].

The Bone Marrow Biopsy

If your high eosinophil count persists without a clear cause, a bone marrow biopsy is often considered, especially for unexplained high counts or suspected clonal disease [2]. This test looks at the “factory” where your blood cells are made. Your doctor is looking for:

  • Cellularity: Is the marrow over-crowded (hypercellular) with too many cells [7]?
  • Megakaryocyte Morphology: These are the cells that make platelets. Abnormal-looking megakaryocytes (dysmegakaryopoiesis) can point toward a clonal myeloid neoplasm [8].
  • Fibrosis: This is scarring in the bone marrow, often graded on a scale (e.g., Grade 1 reticulin fibrosis), which can affect how well your marrow functions [8].

Checking for “Silent” Heart Damage

Eosinophils have a “predilection” for the heart, and damage can occur even if you feel perfectly fine [9].

  • Blood Biomarkers: Tests for troponin and BNP (or NT-proBNP) can detect tiny amounts of heart muscle stress or injury. Note that these are screening clues, and do not definitively exclude disease [9][10].
  • Echocardiogram: This ultrasound of the heart is usually the first imaging step. It looks for blood clots in the heart chambers or signs of the heart walls becoming “restrictive” or stiff [11][12].
  • Cardiac MRI (CMR): This test is valuable for myocardial tissue characterization. It is more sensitive than an echocardiogram for finding early-stage inflammation (myocarditis) or small clots that might be hidden [9][13]. The choice of imaging depends on symptoms, ECG, and biomarkers [14].

Your Completeness Checklist

When reviewing your lab results and pathology reports, ensure these key elements are addressed. If they are missing, they are excellent topics to bring up with your specialist.

1. Essential Lab Markers

  • Absolute Eosinophil Count (AEC): The total number, not just the percentage [15].
  • Vitamin B12 & Tryptase: High levels of these can sometimes support suspicion for a clonal/genetic cause, though they are not diagnostic alone [16].
  • ANCA Status: Used to screen for vasculitis like EGPA [17].
  • Troponin & BNP: To monitor for heart involvement [9].
  • Strongyloides Serology: Essential parasite screening, especially if you have relevant travel or residence history, as corticosteroids can precipitate life-threatening hyperinfection.

2. Genetic Mutation Panel

Many clonal eosinophilic disorders are caused by specific “fusion genes.” These often require specialized tests like FISH (Fluorescence In Situ Hybridization) or RT-PCR [18][8].

  • PDGFRA (specifically the FIP1L1-PDGFRA fusion)
  • PDGFRB
  • FGFR1
  • JAK2 (including PCM1-JAK2)
  • KIT D816V (often associated with mast cell issues) [19]

3. Bone Marrow Findings

  • Blast Percentage: Should be clearly stated [4].
  • Eosinophil Burden: The percentage of marrow cells that are eosinophils [7].
  • Reticulin Stain: To check for the presence and grade of fibrosis (scarring) [8].

Common questions in this guide

How is persistent hypereosinophilia diagnosed?
Doctors usually start with a repeat complete blood count, a review of medications and exposures, and tests for secondary causes such as allergies, inflammation, or parasites. A blood smear, bone marrow biopsy, genetic testing, or imaging may be added based on the results and your symptoms.
Why would I need a bone marrow biopsy for high eosinophils?
A bone marrow biopsy examines where blood cells are made and can help distinguish a reactive increase from a bone marrow disorder. It can show the number of immature cells, the eosinophil burden, the appearance of platelet-making cells, and scarring called fibrosis.
What can a blood smear reveal about eosinophils and platelets?
A peripheral blood smear lets a pathologist examine blood cells under a microscope. It can identify immature cells, unusual eosinophil shapes, or platelet clumping that may explain an abnormal platelet count.
How is heart damage checked when eosinophil levels are high?
Blood tests for troponin and BNP can look for heart muscle stress, while an echocardiogram checks heart function, stiffness, and clots. If concern remains, cardiac MRI can provide a more detailed look for early inflammation or small clots, even when symptoms are absent.
What do FIP1L1-PDGFRA and other gene tests look for?
Specialized tests such as FISH or RT-PCR look for fusion genes and other changes linked to clonal eosinophilic disorders. The panel may include PDGFRA, including the FIP1L1-PDGFRA fusion, PDGFRB, FGFR1, JAK2 including PCM1-JAK2, and KIT D816V.
Why is Strongyloides testing important before corticosteroids?
A Strongyloides blood test may be recommended when travel or residence history suggests exposure to this parasite. Corticosteroids can allow an undetected infection to spread rapidly and become life-threatening, so screening can help guide safer treatment.

Get notified when new evidence is published on platelet abnormalities with eosinophilia and immune-mediated inflammatory disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (19)
  1. 1

    French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes.

    Groh M, Rohmer J, Etienne N, et al.

    Orphanet journal of rare diseases 2023; (18(1)):100 doi:10.1186/s13023-023-02696-4.

    PMID: 37122022
  2. 2

    World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.

    Shomali W, Gotlib J

    American journal of hematology 2024; (99(5)):946-968 doi:10.1002/ajh.27287.

    PMID: 38551368
  3. 3

    From hypereosinophilia to hypereosinophilic syndrome: real-world application of a two-tailed approach for HES diagnosis.

    Nicola S, Borrelli R, Ridolfi I, et al.

    Frontiers in immunology 2025; (16()):1735131 doi:10.3389/fimmu.2025.1735131.

    PMID: 41567200
  4. 4

    Diagnostic spectrum of hypereosinophilia based on bone marrow pathology: 10 years' experience at a tertiary care hospital.

    Kim H, Cho YU

    International journal of laboratory hematology 2023; (45(3)):328-336 doi:10.1111/ijlh.14025.

    PMID: 36756990
  5. 5

    Acute Myeloid Leukaemia With Translocation (8;21) Masquerading as Peripheral Blood Eosinophilia Having Dysplastic Features: A Diagnostic Challenge.

    Singh A, Tripathi T, Singh A, et al.

    Cureus 2023; (15(1)):e33858 doi:10.7759/cureus.33858.

    PMID: 36819451
  6. 6

    Blood and Bone Marrow Evaluation for Eosinophilia.

    Boyer DF

    Archives of pathology & laboratory medicine 2016; (140(10)):1060-7 doi:10.5858/arpa.2016-0223-RA.

    PMID: 27684977
  7. 7

    Case Report: Pediatric myeloid/lymphoid neoplasm with eosinophilia and PDGFRA rearrangement: The first case presenting as B-lymphoblastic lymphoma.

    Akiely R, Almasri F, Almasri N, Abu-Ghosh A

    Frontiers in pediatrics 2022; (10()):1059527 doi:10.3389/fped.2022.1059527.

    PMID: 36589160
  8. 8

    MPRIP::PDGFRB fusion identified in a male patient with a myeloid/lymphoid neoplasm with eosinophilia.

    Gao M, Bachiashvili K, Jamy O, et al.

    Annals of hematology 2026; (105(5)).

    PMID: 42043473
  9. 9

    Hypereosinophilic syndrome: considerations for the cardiologist.

    Bondue A, Carpentier C, Roufosse F

    Heart (British Cardiac Society) 2022; (108(3)):164-171 doi:10.1136/heartjnl-2020-317202.

    PMID: 34172539
  10. 10

    [Risk Factors and Prognosis of Cardiovascular Damage in Hypereosinophilia].

    Zhang WJ, Zhang QK, Wei XF, et al.

    Zhongguo shi yan xue ye xue za zhi 2023; (31(3)):810-815 doi:10.19746/j.cnki.issn.1009-2137.2023.03.028.

    PMID: 37356944
  11. 11

    Hypereosinophilic syndrome: cardiac diagnosis and management.

    Mankad R, Bonnichsen C, Mankad S

    Heart (British Cardiac Society) 2016; (102(2)):100-6 doi:10.1136/heartjnl-2015-307959.

    PMID: 26567231
  12. 12

    Loeffler's Endocarditis: An Integrated Multimodality Approach.

    Polito MV, Hagendorff A, Citro R, et al.

    Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 2020; (33(12)):1427-1441 doi:10.1016/j.echo.2020.09.002.

    PMID: 33129649
  13. 13

    The Cleveland Clinic experience of eosinophilic myocarditis in the setting of hypereosinophilic syndrome: demographics, cardiac imaging, and outcomes.

    Reeder M, Okushi Y, Lo Presti Vega S, et al.

    Cardiovascular diagnosis and therapy 2024; (14(6)):1122-1133 doi:10.21037/cdt-24-347.

    PMID: 39790190
  14. 14

    Fulminant Idiopathic Hypereosinophilic Syndrome Presenting with Cardiac, Neurologic and Haematologic Involvement.

    Ibrahim N, Batri A, Rivera RR, Zwein A

    European journal of case reports in internal medicine 2025; (12(12)):006010 doi:10.12890/2025_006010.

    PMID: 41536447
  15. 15

    An Approach to the Evaluation of Persistent Hypereosinophilia in Pediatric Patients.

    Schwartz JT, Fulkerson PC

    Frontiers in immunology 2018; (9()):1944 doi:10.3389/fimmu.2018.01944.

    PMID: 30233571
  16. 16

    Development and Validation of the FIP Score for the Screening of FIP1L1::PDGFRA-Associated Hypereosinophilic Syndrome.

    Stammler R, Vallée A, Rohmer J, et al.

    The journal of allergy and clinical immunology. In practice 2025; (13(11)):3066-3076.e2 doi:10.1016/j.jaip.2025.09.009.

    PMID: 40992688
  17. 17

    Eosinophilic granulomatosis with polyangiitis - Advances in pathogenesis, diagnosis, and treatment.

    Fijolek J, Radzikowska E

    Frontiers in medicine 2023; (10()):1145257 doi:10.3389/fmed.2023.1145257.

    PMID: 37215720
  18. 18

    Severe Prolonged Cough as Presenting Manifestation of FIP1L1-PDGFRA+ Chronic Eosinophilic Leukaemia: A Widely Ignored Association.

    Roufosse F, Heimann P, Lambert F, et al.

    Respiration; international review of thoracic diseases 2016; (91(5)):374-9 doi:10.1159/000446076.

    PMID: 27164940
  19. 19

    KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance.

    Schwaab J, Umbach R, Metzgeroth G, et al.

    American journal of hematology 2015; (90(9)):774-7 doi:10.1002/ajh.24075.

    PMID: 26017288

This page explains tests used to investigate persistent hypereosinophilia for educational purposes and does not replace medical advice. Your hematologist and other specialists should interpret your results and decide which tests you need.